Nadine Bews
Well-Known Member
https://kmlaw.ca/cases/liability-for-opioid-epidemic/
Koskie Minsky LLP in Toronto commenced a class action against 28 major pharmaceutical companies (see below). The action was commenced on behalf of all persons in Canada who were prescribed and became addicted to opioids.
This class action seeks to include all persons in Canada, except for excluded person, who were prescribed Opioids and subsequently developed an addiction to Opioids.
"Opioids" means any product marketed by the Defendants which contained any substance from the family of synthetic narcotic pain medications which resemble naturally occurring opiates, including, but not limited to, codeine, morphine, hydromorphone and fentanyl.
"Family Law Class" and "Family Law Class Members" means all persons within Canada, except for excluded persons, who by reason of his or her relationship to a Class Member have standing pursuant to s. 61(1) of the Family Law Act, R.S.O. 1990, c. F.3, or equivalent legislation in other provinces and territories;
"Excluded Persons" means any person entitled to recover damages in the action bearing Court File Number 07-CV-343201CP and any officer or director of any of the Defendants.
The Statement of Claim, issued in the Ontario Superior Court of Justice on May 15, 2019, alleges that the 28 pharmaceutical companies commenced a campaign promoting the use of opioids for various chronic conditions in the 1990s, which led to widespread addiction among individuals who were prescribed those medications.
This action comes on the heels of medical findings that opioids are no more effective than NSAIDS at treating many chronic conditions for which they are routinely prescribed. The lawsuit alleges that manufactures knew of this limited efficacy, and the significant risk of addiction, but promoted their products for these uses anyway.
The claim alleges that the defendants conspired, and were negligent in their research, development, manufacture, testing, regulatory licencing, distribution, sale and marketing of opioids. The lawsuit seeks $1.1 billion in damages.
It would be helpful if you could respond to this email with the following information:
1. Your full name;
2. Name of the person the opioids were prescribed to;
a. What is the name of the prescribed opioid(s)?
b. In what year was the opioid prescription issued to you?
3. Which of the following pharmaceutical companies produced the opioids you were prescribed?
a. APOTEX INC.
b. APOTEX PHARMACEUTICAL HOLDINGS, INC
c. BRISTOL-MYERS SQUIBB CANADA 1959
d. BRISTOL-MYERS SQUIBB COMPANY
e. PALADIN LABS
f. ENDO PHARMACEUTICALS INC
g. ENDO INTERNATIONAL PLC
h. JANSSEN INC.
i. JOHNSON & JOHNSON
j. PHARMASCIENCE INC.
k. JODDES LIMITED
l. PRO DOC LIMITEE
m. THE JEAN COUTU GROUP (PJC) INC.
n. MYLAN PHARMACEUTICALS ULC
o. MYLAN N.V
p. PURDUE PHARMA INC.
q. PURDUE PHARMA L.P.
r. THE PURDUE FREDERICK COMPANY
s. PURDUE FREDERICK INC.
t. RANBAXY PHARMACEUTICALS CANADA INC.
u. SUN PHARMACEUTICAL INDUSTRIES LTD.
v. HIKMA LABS INC.
w. HIKMA PHARMACEUTICALS PLC
x. WEST-WARD COLUMBUS INC.
y. SANIS HEALTH INC.
z. SANDOZ CANADA INC.
aa. TEVA CANADA LIMITED
bb. TEVA PHARMACEUTICALS USA, INC.
cc. TEVA PHARMACEUTICAL INDUSTRIES LTD.
dd. ACTAVIS PHARMA COMPANY
ee. VALEANT CANADA LP/ VALEANT CANADA S.E.C.
ff. BAUSCH HEALTH COMPANIES INC.
gg. AMERISOURCEBERGEN CANADA CORPORATION
hh. KOHL & FRISCH DISTRIBUTION INC.
ii. NU-QUEST DISTRIBUTION INC.
jj. ABBOTT LABORATORIES INC.
kk. PROCURITY INC.
ll. Other, please specify:
4. Your telephone number;
5. Your complete mailing address;
6. Your email address;
7. Whether you would be willing and able to speak to our lawyers should we wish to obtain further information; and
8. Whether you would be willing and able to swear an affidavit?
If you would like to speak with a lawyer about these sensitive issues, please let us know and a lawyer will call you.
A copy of the statement of claim is available here: https://kmlaw.ca/wp-content/uploads/2019/05/Statement-of-Claim-Issued-May-15-2019.pdf
Should you have any further questions, please do not hesitate to contact us.
Regards,
Communications Department
Koskie Minsky LLP | Barristers & Solicitors
T 1 833 630 1776| F 416-204-2897 | E opioidclassaction@kmlaw.ca
https://kmlaw.ca/cases/liability-for-opioid-epidemic/.
Koskie Minsky LLP in Toronto commenced a class action against 28 major pharmaceutical companies (see below). The action was commenced on behalf of all persons in Canada who were prescribed and became addicted to opioids.
This class action seeks to include all persons in Canada, except for excluded person, who were prescribed Opioids and subsequently developed an addiction to Opioids.
"Opioids" means any product marketed by the Defendants which contained any substance from the family of synthetic narcotic pain medications which resemble naturally occurring opiates, including, but not limited to, codeine, morphine, hydromorphone and fentanyl.
"Family Law Class" and "Family Law Class Members" means all persons within Canada, except for excluded persons, who by reason of his or her relationship to a Class Member have standing pursuant to s. 61(1) of the Family Law Act, R.S.O. 1990, c. F.3, or equivalent legislation in other provinces and territories;
"Excluded Persons" means any person entitled to recover damages in the action bearing Court File Number 07-CV-343201CP and any officer or director of any of the Defendants.
The Statement of Claim, issued in the Ontario Superior Court of Justice on May 15, 2019, alleges that the 28 pharmaceutical companies commenced a campaign promoting the use of opioids for various chronic conditions in the 1990s, which led to widespread addiction among individuals who were prescribed those medications.
This action comes on the heels of medical findings that opioids are no more effective than NSAIDS at treating many chronic conditions for which they are routinely prescribed. The lawsuit alleges that manufactures knew of this limited efficacy, and the significant risk of addiction, but promoted their products for these uses anyway.
The claim alleges that the defendants conspired, and were negligent in their research, development, manufacture, testing, regulatory licencing, distribution, sale and marketing of opioids. The lawsuit seeks $1.1 billion in damages.
It would be helpful if you could respond to this email with the following information:
1. Your full name;
2. Name of the person the opioids were prescribed to;
a. What is the name of the prescribed opioid(s)?
b. In what year was the opioid prescription issued to you?
3. Which of the following pharmaceutical companies produced the opioids you were prescribed?
a. APOTEX INC.
b. APOTEX PHARMACEUTICAL HOLDINGS, INC
c. BRISTOL-MYERS SQUIBB CANADA 1959
d. BRISTOL-MYERS SQUIBB COMPANY
e. PALADIN LABS
f. ENDO PHARMACEUTICALS INC
g. ENDO INTERNATIONAL PLC
h. JANSSEN INC.
i. JOHNSON & JOHNSON
j. PHARMASCIENCE INC.
k. JODDES LIMITED
l. PRO DOC LIMITEE
m. THE JEAN COUTU GROUP (PJC) INC.
n. MYLAN PHARMACEUTICALS ULC
o. MYLAN N.V
p. PURDUE PHARMA INC.
q. PURDUE PHARMA L.P.
r. THE PURDUE FREDERICK COMPANY
s. PURDUE FREDERICK INC.
t. RANBAXY PHARMACEUTICALS CANADA INC.
u. SUN PHARMACEUTICAL INDUSTRIES LTD.
v. HIKMA LABS INC.
w. HIKMA PHARMACEUTICALS PLC
x. WEST-WARD COLUMBUS INC.
y. SANIS HEALTH INC.
z. SANDOZ CANADA INC.
aa. TEVA CANADA LIMITED
bb. TEVA PHARMACEUTICALS USA, INC.
cc. TEVA PHARMACEUTICAL INDUSTRIES LTD.
dd. ACTAVIS PHARMA COMPANY
ee. VALEANT CANADA LP/ VALEANT CANADA S.E.C.
ff. BAUSCH HEALTH COMPANIES INC.
gg. AMERISOURCEBERGEN CANADA CORPORATION
hh. KOHL & FRISCH DISTRIBUTION INC.
ii. NU-QUEST DISTRIBUTION INC.
jj. ABBOTT LABORATORIES INC.
kk. PROCURITY INC.
ll. Other, please specify:
4. Your telephone number;
5. Your complete mailing address;
6. Your email address;
7. Whether you would be willing and able to speak to our lawyers should we wish to obtain further information; and
8. Whether you would be willing and able to swear an affidavit?
If you would like to speak with a lawyer about these sensitive issues, please let us know and a lawyer will call you.
A copy of the statement of claim is available here: https://kmlaw.ca/wp-content/uploads/2019/05/Statement-of-Claim-Issued-May-15-2019.pdf
Should you have any further questions, please do not hesitate to contact us.
Regards,
Communications Department
Koskie Minsky LLP | Barristers & Solicitors
T 1 833 630 1776| F 416-204-2897 | E opioidclassaction@kmlaw.ca
https://kmlaw.ca/cases/liability-for-opioid-epidemic/.